Form 4 for FATE FATE THERAPEUTICS INC
Accepted 2026-01-12 00:00:00 ET · period of report 2026-01-09 · accession 0001193125-26-010352 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-12 | 2026-01-09 | FATE | Valamehr Bahram | Pres, CEO, Dir | S - Sale | $1.07 | -5,190 | 329.7K | -2% | -$5,553 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-09 | S | D | 5,190 | $1.07 | 329,708 | D | — | — | (F2) Represents the weighted average sale price of the shares sold ranging from $1.055 to $1.085 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. |